1. Home
  2. TWN vs TVRD Comparison

TWN vs TVRD Comparison

Compare TWN & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TWN
  • TVRD
  • Stock Information
  • Founded
  • TWN 1986
  • TVRD 2017
  • Country
  • TWN Hong Kong
  • TVRD United States
  • Employees
  • TWN N/A
  • TVRD N/A
  • Industry
  • TWN Trusts Except Educational Religious and Charitable
  • TVRD Biotechnology: Pharmaceutical Preparations
  • Sector
  • TWN Finance
  • TVRD Health Care
  • Exchange
  • TWN Nasdaq
  • TVRD Nasdaq
  • Market Cap
  • TWN 305.8M
  • TVRD 246.5M
  • IPO Year
  • TWN N/A
  • TVRD N/A
  • Fundamental
  • Price
  • TWN $54.71
  • TVRD $38.74
  • Analyst Decision
  • TWN
  • TVRD Strong Buy
  • Analyst Count
  • TWN 0
  • TVRD 5
  • Target Price
  • TWN N/A
  • TVRD $59.20
  • AVG Volume (30 Days)
  • TWN 20.1K
  • TVRD 31.5K
  • Earning Date
  • TWN 01-01-0001
  • TVRD 08-14-2025
  • Dividend Yield
  • TWN 1.10%
  • TVRD N/A
  • EPS Growth
  • TWN N/A
  • TVRD N/A
  • EPS
  • TWN N/A
  • TVRD N/A
  • Revenue
  • TWN N/A
  • TVRD N/A
  • Revenue This Year
  • TWN N/A
  • TVRD N/A
  • Revenue Next Year
  • TWN N/A
  • TVRD N/A
  • P/E Ratio
  • TWN N/A
  • TVRD N/A
  • Revenue Growth
  • TWN N/A
  • TVRD N/A
  • 52 Week Low
  • TWN $25.22
  • TVRD $8.13
  • 52 Week High
  • TWN $41.51
  • TVRD $40.77
  • Technical
  • Relative Strength Index (RSI)
  • TWN 75.80
  • TVRD 74.43
  • Support Level
  • TWN $53.00
  • TVRD $33.51
  • Resistance Level
  • TWN $54.50
  • TVRD $36.71
  • Average True Range (ATR)
  • TWN 0.85
  • TVRD 2.31
  • MACD
  • TWN 0.14
  • TVRD 0.70
  • Stochastic Oscillator
  • TWN 95.45
  • TVRD 83.85

About TWN Taiwan Fund Inc. (The)

Taiwan Fund Inc is a diversified closed-end management investment company. Its investment objective is to seek long-term capital appreciation through investment predominantly in equity securities listed in Taiwan stock exchange and the Republic of China. In selecting the companies for investments fund's portfolio managers will consider overall growth prospects, competitive position in the respective industry technology, research, and development, productivity, profit margins, return on investment, capital resources, government regulation, management and other factors.

About TVRD Tvardi Therapeutics Inc. Common Stock

Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Share on Social Networks: